Item 2.02 Results of Operations and Financial Condition.
Precigen, Inc. (the “Company”) hereby furnishes the following estimates with
respect to its preliminary financial updates as of December 31, 2022:
· Cash, cash equivalents, short-term and long-term investments totaled
approximately $56.0 million as of December 31, 2022;
· Restricted cash of approximately $43.7 million as of December 31, 2022, of
which approximately $43.4 million was restricted for certain permitted purposes,
including the resolution of the Company’s outstanding 3.50% convertible senior
notes due 2023; and
· The face value of the Company’s outstanding 3.50% convertible senior notes
due 2023 as of December 31, 2022 was approximately $43.4 million and convertible
into approximately 2,542,000 shares of the Company’s common stock.
The information set forth above is preliminary and unaudited and reflects
preliminary financial information as of and for the year ended December 31,
2022. In preparing this information, the Company’s actual results for the year
ended December 31, 2022 have not yet been finalized by management or reviewed or
audited by the Company’s independent registered public accounting firm. The
foregoing results are also not a comprehensive statement of financial results as
of and for the year ended December 31, 2022. Subsequent information or events
may lead to material differences between the foregoing preliminary financial
information and those reported in the Company’s subsequent SEC filings.
Accordingly, investors should not place undue reliance on this preliminary
Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 is a copy of a press release of the Company, dated
January 24, 2023, providing an overview of certain research and development
updates that the Company intends to present during a conference call.
This information, including the Exhibit attached hereto, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, except as shall be expressly set forth by specific reference in
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Press Release issued by Precigen, Inc., dated January 24, 2023. 99.1 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source Glimpses